Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit HORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor …
Read More
Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026
Published: March 04, 2026 by: 24/7 Wall Street
Sentiment: Positive
Volatility is again picking up, and it's a good idea to focus more on safety.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Wasatch Global Value Fund Q4 2025 Performance Review
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive
Production volumes for Samsung's foundry business have been boosted by demand for HBM chips. Johnson & Johnson announced plans to spin its orthopedics business (joint replacements, surgical tools, etc.) out of its med tech division in order to focus more tightly on higher-growth areas such as oncology. While VICI's most recent earnings results were modestly positive, a meaningful softening in casino revenues weighed on the stock in the quarter.
Read More
Retire Comfortably With These Dividend Growth Stocks
Published: March 03, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Of all the retirement activities you can engage in, worrying about your financial security shouldn't be one of them.
Read More
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.
Read More
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Read More
Best Dividend Aristocrats For March 2026
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
Read More
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson's JNJ stock has risen 38.4% in the past six months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) for more than eight months since mid-June 2025 due to its positive earnings outlook and improving fundamentals.
Read More
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer RARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the foundational gold standard treatment.
Read More
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Published: February 23, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Read More
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
Johnson & Johnson is a core player in global healthcare. A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing dividend.
Read More
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility
Published: February 19, 2026 by: Fox Business
Sentiment: Positive
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
Read More
2 High-Yield CEFs To Enhance Your Retirement Income
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
2 High-Yield CEFs To Enhance Your Retirement Income
Read More
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
Published: February 18, 2026 by: WSJ
Sentiment: Positive
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
Read More
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
Published: February 18, 2026 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Published: February 18, 2026 by: 24/7 Wall Street
Sentiment: Positive
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different.
Read More
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
Read More
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
Published: February 13, 2026 by: Reuters
Sentiment: Negative
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.
Read More
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within its pharmaceuticals division, called Innovative Medicine. The company has several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH) and infectious diseases.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
The Big 3: JNJ, XOM, KO
Published: February 05, 2026 by: Schwab Network
Sentiment: Neutral
Thursday's trading action is what Dan Deming calls a "tummy tester" with tech taking another gut punch and Bitcoin dropping to November 2024 lows. Dan turns to defensive stocks for his Big 3, offering example options trades for Johnson & Johnson (JNJ), Exxon Mobil (XOM), and Coca-Cola (KO).
Read More
What's Behind The 50% Surge In JNJ Stock?
Published: February 03, 2026 by: Forbes
Sentiment: Positive
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements, and advancements in legal matters. Behind this 3.2% uplift in revenue and enhancement in margins is a narrative of innovation, effective risk management, and strategic evolution—let's delve into what has influenced this change.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100